Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on November 6, 2019. The registrant is a Delaware corporation headquartered in San Diego, California, with common stock trading on the Nasdaq Capital Market under the symbol TROV. The filing reports a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-driven report and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the acceptance of clinical trial data for presentation at a major industry conference. Specifically, data from Trovagene's completed Phase 1b and ongoing Phase 2 study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML) has been accepted for an oral presentation.
Guidance, Outlook, and Management Commentary
- Event Details: The data will be presented at the 61st American Society of Hematology (ASH) Annual Meeting.
- Date and Location: December 7 - 10, 2019, in Orlando, Florida.
- Management Commentary: The filing references a press release (Exhibit 99.1) for further details but contains no specific financial guidance, risk factors, or contingencies within the body of this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific clinical data results.
- Confirm the presentation schedule and abstract details at the 61st ASH Annual Meeting.
- Review the company's latest 10-Q or 10-K filings for current financial status, as this 8-K contains no financial data.
- Note the registrant name is Trovagene, Inc., distinct from Cardiff Oncology, Inc.